Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Abbott Laboratories (NYSE:ABT)

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on March 09th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on February 10th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Thermon Group (NYSE:THR) on 3/2/2026.
• Purchased $1,001 – $15,000 in shares of Federal Signal (NYSE:FSS) on 3/2/2026.
• Purchased $1,001 – $15,000 in shares of Taiwan Semiconductor Manufacturing (NYSE:TSM) on 2/26/2026.
• Sold $1,001 – $15,000 in shares of Uber Technologies (NYSE:UBER) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Robinhood Markets (NASDAQ:HOOD) on 2/24/2026.
• Purchased $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 2/24/2026.
• Sold $1,001 – $15,000 in shares of Oracle (NYSE:ORCL) on 2/24/2026.
• Purchased $1,001 – $15,000 in shares of Champion Homes (NYSE:SKY) on 2/23/2026.
• Sold $1,001 – $15,000 in shares of Tri Pointe Homes (NYSE:TPH) on 2/23/2026.
• Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 2/20/2026.

Abbott Laboratories Trading Down 1.9%

Abbott Laboratories stock traded down $2.07 during trading hours on Thursday, reaching $108.18. 10,837,207 shares of the company’s stock were exchanged, compared to its average volume of 10,536,449. The firm’s 50 day simple moving average is $115.25 and its 200 day simple moving average is $124.19. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $139.06. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $187.98 billion, a PE ratio of 29.08, a PEG ratio of 1.76 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last announced its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same quarter in the prior year, the company earned $1.34 EPS. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Insider Buying and Selling

In other Abbott Laboratories news, SVP Eric Shroff sold 709 shares of the business’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $81,946.22. Following the transaction, the senior vice president owned 39,164 shares of the company’s stock, valued at approximately $4,526,575.12. The trade was a 1.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the firm’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the sale, the executive vice president directly owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. This represents a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,055 shares of company stock valued at $353,097 over the last quarter. Corporate insiders own 0.46% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on ABT shares. Sanford C. Bernstein cut their price target on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Royal Bank Of Canada dropped their target price on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Argus cut their target price on shares of Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Leerink Partners decreased their price target on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research note on Friday, January 30th. Finally, Raymond James Financial dropped their price objective on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $136.16.

Hedge Funds Weigh In On Abbott Laboratories

A number of hedge funds have recently added to or reduced their stakes in the stock. Charles Schwab Trust Co raised its holdings in shares of Abbott Laboratories by 109.8% in the third quarter. Charles Schwab Trust Co now owns 29,412 shares of the healthcare product maker’s stock valued at $3,939,000 after purchasing an additional 15,394 shares during the last quarter. Asset Management One Co. Ltd. boosted its holdings in Abbott Laboratories by 2.4% during the third quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock worth $115,032,000 after purchasing an additional 19,966 shares during the last quarter. Nordea Investment Management AB grew its position in Abbott Laboratories by 6.1% in the 3rd quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock worth $43,785,000 after purchasing an additional 18,974 shares in the last quarter. AE Wealth Management LLC increased its stake in Abbott Laboratories by 20.8% in the 3rd quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock valued at $8,774,000 after buying an additional 11,264 shares during the last quarter. Finally, Mawer Investment Management Ltd. lifted its position in shares of Abbott Laboratories by 5.9% during the 3rd quarter. Mawer Investment Management Ltd. now owns 1,255,780 shares of the healthcare product maker’s stock worth $168,199,000 after buying an additional 70,122 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Randomized‑controlled FreeDM2 trial: Abbott’s FreeStyle Libre CGM showed better HbA1c reduction (−0.6%) and ~2.5 more hours/day in range versus fingersticks for people with Type 2 on basal insulin — data that supports broader clinical use and potential revenue upside for Libre adoption. Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management
• Positive Sentiment: Clinical reinforcement across publications: a complementary Italian study reported similar improvements, strengthening the evidence base for Libre in a larger Type 2 patient population and supporting long‑term growth expectations for Abbott’s diabetes franchise. Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management
• Positive Sentiment: Brand and marketing push: Abbott launched year two of the “Abbott Dream Team” with Real Madrid to build brand awareness and youth engagement in the U.S., a low‑cost marketing play that can help consumer-facing product adoption and long‑term brand equity. Abbott and Real Madrid launch nationwide effort to build the next ‘Abbott Dream Team’
• Neutral Sentiment: Q4 context overview: Coverage comparing Abbott to medical-device peers highlights mixed Q4 performance — revenue and margins grew but some metrics lagged consensus — useful for relative valuation but not an immediate catalyst. Q4 Earnings Highs And Lows: Abbott Laboratories (NYSE:ABT) Vs The Rest Of The Medical Devices & Supplies – Diversified Stocks
• Neutral Sentiment: Analyst views mixed but stable fair value: A note shows modeled fair value effectively unchanged (US$133.39 → US$133.33) while analysts rework targets and risks — indicates differing opinions but no large consensus pivot. How The Story On Abbott Laboratories (ABT) Is Shifting As Analysts Rework Targets And Risks
• Neutral Sentiment: Long‑term investor commentary: Pieces highlighting Abbott as a value or dividend name reinforce buy‑and‑hold narratives but are unlikely to move the stock immediately. Why Abbott (ABT) is a Top Value Stock for the Long-Term
• Negative Sentiment: Analyst price‑target trim: Citigroup reduced its price target from $140 to $136 while keeping a buy rating — a modest downgrade that can weigh on sentiment and contribute to near‑term downside pressure. Benzinga note on Citigroup price target change

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.